Literature DB >> 21575992

Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction.

Rachel Morehouse1, Glenda Macqueen, Sidney H Kennedy.   

Abstract

BACKGROUND: Patients who meet the criteria for a major depressive episode experience a constellation of symptoms, and different symptom configurations may reflect distinct underlying neurological disturbances. Similarly, the differing receptor profiles of the various antidepressants may explain relatively low remission rates and persistent symptoms even after remission. In particular, depressed patients frequently display altered circadian rhythms, sleep disturbances, and diurnal mood variation. Exploring treatments that can restore mood while having a positive impact on circadian rhythms and sleep would greatly improve the ability to treat this core features of depression.
METHODS: The mechanisms of action of the various classes of antidepressants, their effects on sleep and issues beyond sleep, including sexual dysfunction, are explored, along with questions relating to adherence.
RESULTS: Unfortunately, persistent sleep problems are among the most difficult-to-treat residual symptoms of depression. Many of the currently available antidepressants have adverse effects on circadian processes, including sleep, and may actually worsen sleep problems. Tolerability is also an enduring issue; SSRI and SNRI antidepressants are associated with central nervous sysytem and gastrointestinal effects, sexual side effects and suicidality. Improved drug tolerability would not only minimize distressing adverse effects, but would also improve adherence, thus maximizing the chances of successful treatment.
CONCLUSIONS: The complexity of managing a major depressive episode is well illustrated by sleep disturbance and sexual dysfunction, two core symptoms of MDD that may also be caused or exacerbated by antidepressant therapy. Future antidepressants should alleviate symptoms without adversely affecting sleep or sexual function.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21575992     DOI: 10.1016/j.jad.2011.03.047

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  6 in total

Review 1.  Genetic endophenotypes for insomnia of major depressive disorder and treatment-induced insomnia.

Authors:  Ibrahim Mohammed Badamasi; Munn Sann Lye; Normala Ibrahim; Johnson Stanslas
Journal:  J Neural Transm (Vienna)       Date:  2019-05-18       Impact factor: 3.575

2.  Factors influencing fluoxetine-induced sexual dysfunction in female rats.

Authors:  Sarah Adams; Danyeal Heckard; James Hassell; Lynda Uphouse
Journal:  Behav Brain Res       Date:  2012-07-23       Impact factor: 3.332

3.  Sprague-Dawley and Fischer female rats differ in acute effects of fluoxetine on sexual behavior.

Authors:  Chandra Suma J Miryala; Cindy Hiegel; Lynda Uphouse
Journal:  J Sex Med       Date:  2012-10-30       Impact factor: 3.802

4.  Psychotropic prescription patterns among patients diagnosed with depressive disorder based on claims database in Japan.

Authors:  Yoshie Onishi; Shiro Hinotsu; Toshiaki A Furukawa; Koji Kawakami
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

5.  The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials.

Authors:  Guangjian Li; Xu Wang; Dihui Ma
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-29       Impact factor: 2.570

6.  Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.

Authors:  Andrew A Crawford; Sarah Lewis; David Nutt; Tim J Peters; Philip Cowen; Michael C O'Donovan; Nicola Wiles; Glyn Lewis
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.